Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer

Inclusion Criteria: * Histologically and/or cytologically proven locally advanced pancreatic adenocarcinoma * Target lesion is technically amenable for Alpha DaRT sources implantation. * Measurable lesion per RECIST (version 1.1) criteria * Stable disease or tumor response per RECIST (version 1.1) criteria compared to before initiation of mFOLFIRINOX * Lesion size ≤ 5 cm in the longest diameter * Interstitial radiation indication validated by a multidisciplinary team which includes an oncologist, a radiation oncologist, radiologist, gastroenterologist and a surgeon specialized in pancreatic oncology in the case that a surgical emergency occurs during the procedure * Patients have received 8 - 12 cycles of mFOLFIRINOX * ECOG Performance Status Scale 0 - 1 * Life expectancy is more than 6 months * WBC ≥ 3500/µl, granulocyte ≥ 1500/µl * Platelet count ≥60,000/µl * Creatinine ≤1.9 mg/dL * AST and ALT ≤ 2.5 X upper limit of normal (ULN) * INR \< 1.4 for patients not on Warfarin * Age ≥18 years old * Subjects are willing and able to sign an informed consent form * Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test before the Ra-224 implantation and are required to use an acceptable contraceptive method to prevent pregnancy for 3 months after initiation of Alpha DaRT therapy * Patients must agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 mont…